Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials. - Shaya S; Uche-Ikonne O; Kilerci B; Stevenson J; Greystoke A; Cook N; Thistlethwaite FC; Carter L; Graham DM; Krebs MG (Journal of immunotherapy and precision oncology, 2025)